UK: Pharma And The Connected Patient: How Digital Technology Is Enabling Patient Centricity

Last Updated: 7 August 2017
Article by Mark Steedman

This week we launched our report Pharma and the connected patient: How digital technology is enabling patient centricity. Our report focusses on pharma's efforts to utilise smartphone apps, wearables and other digital technologies in an effort to put patients at the centre of new business and operating models. This transformation, from a provider-driven marketplace to a patient-centric health ecosystem, is being driven by the need to demonstrate value to payers and patients and respond to a variety of powerful forces that are transforming healthcare. These forces are requiring pharma to become more agile and to do more for patients than deliver safe and effective drugs.

Pharma's traditional business model is facing escalating cost and pricing pressures, increasing competition, shorter time in the market, expiring patents, declining profitability and mounting regulatory scrutiny. Thus far, pharma has attempted to address these challenges using traditional business strategies such as mergers, acquisitions and reorganisations, and many companies are also focusing on fewer therapy areas. However, increasingly, pharma companies are realising that a new transformational business model is needed to effectively address their challenges – with a general acknowledgement that they need to engage more effectively with patients and place them at the centre of each part of the pharma value chain. This transition towards a more patient centric approach has the potential to revitalise the industry so that it remains relevant and profitable.

We identify the use of innovative digital technology as a key enabler of this transformation and examine how pharma is beginning to develop more patient-centric strategies, by making effective use of these digital technologies. Our research involved extensive literature reviews, supplemented by primary research that analysed the number and popularity of smartphone apps produced by the top 12 pharma companies. We also surveyed 190 patient groups for their views on how health apps are being used, particularly apps that are produced by the pharma industry.

Our primary research into pharma-produced apps showed that pharma can do more to engage with patients, particularly through the smartphone. While the number of apps produced by the top 12 pharma companies more than tripled between 2013 and 2016 from 305 to 988, the growth rate of these downloads has slowed considerably in the same time frame. In addition, the five most popular of these apps make up just over 50 per cent of these downloads, meaning many of these apps are rarely used. Overall, these pharma-produced apps were downloaded over 5.6 million times in 2016 – a number dwarfed by the 3.2 billion downloads of the 260,000 or so Health apps available in 2016.

Our survey results elucidated some of the reasons behind why pharma-produced apps are less popular than they could be. The patient groups who responded to our survey viewed apps produced by pharma to be less trustworthy than those produced by healthcare professionals, other industries and individuals. Similarly, patient groups were much less willing to share their personal health data with pharma companies than healthcare professionals.

Based on the results of our primary research and our review of the literature, we identified six main challenges the pharma industry is currently facing in becoming more patient-centric:

  • the traditional product-based pharma culture can be at odds with the move to a more agile and responsive patient centric culture – engaging differently with patients' needs requires collaboration and co-ordination among cross-functional teams
  • regulatory uncertainty with regard to digital technology and patient centricity – despite some guidance, the rapid pace of technological advancement is adding to the already complex regulatory landscape, creating uncertainty amongst pharma as to regulators'  expectations and requirements
  • data safety and privacy in the face of the proliferation of medical apps and other digital technologies – in moving from randomised controlled trials and anonymised data collection to collecting identifiable data as part of a more patient-centric approach, pharma needs to ensure the highest levels of data safety, privacy and user consent are maintained
  • corporate reputation can undermine patient engagement with pharma – largely due to past publicity about excessive pricing and a lack of transparency, public confidence has been eroded, reducing patients' willingness to engage with pharma
  • attracting talent with the skills to support a patient-centric ecosystem – pharma's traditional risk averse corporate culture and perceived a lack of agility and 'fail-forward mentality' that normally governs entrepreneurial endeavour can impact recruitment and retention of  digital skills
  • low levels of health and digital literacy impacts patients' ability to engage effectively – with between a third and a half of people having low health literacy, this can undermine patient engagement with mobile health technologies.

We identified five strategies that pharma are adopting to respond to the above challenges, including:

  • change corporate cultures and structures, based on shared values and cross-functional working to promote agility, foster innovation and attract and retain appropriate talent
  • develop partnerships to support the deployment of digital technology, including patient portals and engagement platforms, to help deliver a more patient-centric experience
  • automate processes supporting patient facing activities and optimise use of digital talent – automation can benefit clinical trial management, drug launch monitoring and marketing content approval. The use of digital hubs can optimise deployment of digital talent
  • create new contracting and pricing models, underpinned by patient information and insights, and generated through the use of digital health technology and big data analytics
  • build collaborative relationships with patients, payers, healthcare professionals and regulators to improve health and digital literacy, and predict and manage new risks, including data security and privacy risks. 

We also identified seven actions pharma companies can take to utilise future enablers of patient centricity:

  • embed blockchain technology to improve efficiency, safety and traceability – blockchain's highly secure, decentralised framework for data sharing has the potential to overcome the limitations of large-scale sharing of health data
  • adopt gamification to enhance patient engagement, health literacy and medication adherence – gamification's built-in reward mechanisms can stimulate further play and greater understanding of health conditions
  • use 3D printing to transform all stages of the pharma value chain – more personalised medicine, made possible by 3D printing, can be more cost-effective, can increase productivity and enhance collaboration
  • optimise the potential of the connected patient to develop new outcome-based propositions – pharma companies could become a central player in a learning health ecosystem
  • make patients true partners in managing their own care – pharma will need to embrace patients' increased control of their data and their ability to own, operate and drive their own healthcare
  • utilise non-traditional players' experience of disruptive technologies and customer engagement – pharma will need to engage with technology giants, start-ups and players from other industries to maximise their patient-centric strategies
  • adopt distributed research networks and web-enabled virtual trials – a transformed clinical trial ecosystem will rely on consortia, public-private partnerships and crowdsourcing platforms that will drive new business and research models.

As pharma moves from simply engaging with patients to becoming more patient-centric, pharma will need to listen to the voice of the patient at every stage of the company's business, from drug discovery to winning regulatory approval to post-market disease management. This will help pharma companies improve recruitment and retention in clinical trials, thereby bringing drugs to market that better reflect patient needs; it should also improve medication adherence, resulting in better outcomes, and improved safety monitoring, all of which should help maintain pharma's relevance and sustainability.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement

    Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of www.mondaq.com

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

    Disclaimer

    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

    Registration

    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

    Cookies

    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

    Links

    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

    Mail-A-Friend

    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

    Emails

    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .

    Security

    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at enquiries@mondaq.com.

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions